Quarterly Earnings Releases, Technical Updates, Software Launches, Welfare Initiatives, and New Health Plans - Research Reports on Biogen, Express Scripts, Covidien, Alexion and Aetna

NEW YORK, October 30, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Biogen Idec Inc. (NASDAQ: BIIB), Express Scripts Holding Company (NASDAQ: ESRX), Covidien plc (NYSE: COV), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7558-100free.

--
Biogen Idec Inc. Research Reports
On October 22, 2014, Biogen Idec Inc. (Biogen) announced its Q3 2014 financial results. The Company's total revenues during the quarter rose 37.4% YoY to $2.5 billion which, according to Reuters, were roughly in-line with analyst expectations. Biogen's net income attributable to the Company in Q3 2014 was $856.9 million or $3.62 per diluted share, compared to $487.6 million or $2.05 per diluted share in Q3 2013. Excluding special items, Biogen's net income for Q3 2014 stood at $3.80 per share, exceeding the average expectations by $0.34 per share in a Reuters poll of analysts. Biogen also raised its full-year 2014 EPS guidance. The Company now expects its 2014 non-GAAP EPS to range between $13.45 and $13.55. However, Biogen's better-than-expected Q3 2014 results were overshadowed by concerns over the sales of its big-selling new multiple sclerosis drug Tecfidera which fell short of analyst expectations, sending the Company's stock down by over 5% after earnings release, a Reuters report said. The full research reports on Biogen are available to download free of charge at:

http://www.analystsreview.com/Oct-30-2014/BIIB/report.pdf

--
Express Scripts Holding Company Research Reports
On October 27, 2014, the stock of Express Scripts Holding Company (Express Scripts) fell 0.50% to end the trading session at $73.28. During the session, shares in the Company opened at $73.68 and fluctuated in the range of $73.08 - $73.75, with a total of 4.19 million shares changing hands. Over the last one month, the Company's stock has increased by 2.35%, compared to the Nasdaq Composite index which fell 0.58% during the same period. Moreover, the stock was being traded above its 50-day and 200-day moving averages of $72.87 and $72.10, respectively. The full research reports on Express Scripts are available to download free of charge at:

http://www.analystsreview.com/Oct-30-2014/ESRX/report.pdf

--
Covidien plc Research Reports
On October 27, 2014, Covidien plc (Covidien) announced the launch of a next-generation version of its superDimension™ Navigation System software, featuring a more intuitive interface that helps reduce time spent by physicians planning the procedure and enhances the visualization of the airways of the lung. According to the Company, the latest superDimension planning software uses a patient's CT scan and generates a 3D virtual bronchial tree which lets physicians map pathways aligned with the patient's anatomy to reach pulmonary targets that are used during an electromagnetic navigation bronchoscopy™ (ENB™) procedure. "These advanced tools and technologies demonstrate Covidien's commitment to expanding the specialized lung health products available to pulmonologists and thoracic surgeons," said Chuck Brynelsen, President, Early Technologies, Covidien. The full research reports on Covidien are available to download free of charge at:

http://www.analystsreview.com/Oct-30-2014/COV/report.pdf

--
Alexion Pharmaceuticals, Inc. Research Reports
On October 27, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced the launch of the "Every Day with HPP™" campaign in support of the third annual Hypophosphatasia (HPP) Awareness Week October 26-November 1, 2014. HPP Awareness Week is a national public awareness effort to focus attention on HPP and its impact on patients with HPP and their caregivers, families, friends and supporters. Alexion's Every Day with HPP campaign encourages patients with HPP, caregivers, their loved ones and people interested in supporting the HPP community to share their stories of challenges, hopes and aspirations. Leonard Bell, M.D., Chairman and CEO of Alexion, said, "We are pleased to support the entire HPP community in the effort to raise awareness of this ultra-rare, chronic and progressive disease." The full research reports on Alexion are available to download free of charge at:

http://www.analystsreview.com/Oct-30-2014/ALXN/report.pdf

--
Aetna Inc. Research Reports
On October 23, 2014, Aetna Inc. (Aetna) announced the launch of a new health plan in Washington in collaboration with four provider groups - Pacific Medical Centers (PacMed), The Polyclinic, Providence-Swedish Health Alliance, and Rainier Health Network. The Company's new Aetna Whole HealthSM plan will give members access to coordinated care in King, Snohomish and Pierce counties. According to the Company, the plan's members will be able to select one of the four networks based on geographic and personal preference and will receive an enhanced level of coordinated care when they seek care within their selected network. This product will be available for self-insured customers starting on January 1, 2015 and for fully insured customers in early 2015. The full research reports on Aetna are available to download free of charge at:

http://www.analystsreview.com/Oct-30-2014/AET/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review